Pfizer (PFE) FCF Margin (2009 - 2026)

Pfizer (PFE) has reported FCF Margin for 18 consecutive years, with 2.01% the latest figure, recorded in Q2 2026.

• On a quarterly basis, FCF Margin rose 1020.0% year-over-year to 2.01% in Q2 2026; TTM through Jun 2026 was 17.25%, a 1475.0% increase from a year earlier, with the FY2025 full-year figure at 14.5%, down 96.0% from the prior year.
• FCF Margin was 2.01% for Q2 2026 at Pfizer, down from 15.08% in the prior quarter.
• Over five years, FCF Margin peaked at 122.19% in Q4 2023 and troughed at 18.2% in Q2 2024.
• A 5-year average of 15.76% and a median of 10.85% in 2024 frame the typical range for FCF Margin.
• Across the five-year window, FCF Margin slumped 4308 bps in 2023 and soared 1524 bps in 2025, its largest moves.
• Over 5 years, FCF Margin stood at 26.76% in 2022, then jumped by 357 bps to 122.19% in 2023, then tumbled by 93 bps to 8.79% in 2024, then jumped by 192 bps to 25.65% in 2025, then sank by 92 bps to 2.01% in 2026.
• The last three FCF Margin figures came in at 2.01% (Q2 2026), 15.08% (Q1 2026), and 25.65% (Q4 2025), per Business Quant data.